The obesity drug market will not consolidate into a single dominant player despite fierce competition, Novo Nordisk Chief Executive Lars Fruergaard Jørgensen said on Monday.
Speaking at a media briefing, Jørgensen acknowledged Eli Lilly’s strong position in the sector but emphasized that the market’s scale and patient demand would support multiple competitors. Lilly’s GLP-1 drugs, including Mounjaro and Zepbound, have gained significant traction in obesity treatment, challenging Novo Nordisk’s Ozempic and Wegovy franchises.
The global obesity treatment market is projected to exceed $100 billion by 2030, driven by rising obesity rates and growing adoption of GLP-1 receptor agonists. Novo Nordisk, the current leader in the space, has seen its valuation surge on the back of strong sales of its semaglutide-based therapies. However, Lilly’s rapid market penetration has intensified competition, prompting questions about long-term market dynamics.
Jørgensen noted that the market’s complexity—including varying patient responses, regulatory hurdles, and supply constraints—would prevent a winner-take-all scenario. He highlighted Novo Nordisk’s pipeline of next-generation obesity drugs, including oral formulations, as key differentiators in sustaining its market share.
The CEO also underscored the importance of pricing strategies and access to treatment, particularly in emerging markets where obesity prevalence is rising. Novo Nordisk has committed to expanding its global manufacturing capacity to meet demand, though supply chain challenges remain a near-term risk.
Analysts have warned that pricing pressure could erode margins as more competitors enter the market, but Jørgensen expressed confidence in the sector’s growth potential. "This is a market that will grow significantly, and there is room for multiple players," he said.
